Items where authors include "Collett, C."

Article

Lee, T.T.M. orcid.org/0000-0001-6591-6421, Collett, C., Bergford, S. et al. (18 more authors) (2023) Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. New England Journal of Medicine. ISSN 0028-4793

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Collett, C., Mašek, O., Razali, N. et al. (1 more author) (2020) Influence of biochar composition and source material on catalytic performance : the carboxylation of glycerol with CO2 as a case study. Catalysts, 10 (9). 1067.

Proceedings Paper

Relton, C. orcid.org/0000-0001-8530-5011, Burbach, M., Collett, C. et al. (17 more authors) (2017) 2nd TwiCs symposium summary. In: Trials. ‘Trials within Cohorts’ (TwiCs): 2nd international symposium, 07-08 Nov 2016, London, UK. BioMed Central .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Pawlyn, C., Davies, F.E., Kaiser, M.F. et al. (18 more authors) (2016) Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .